BergenBio: ASCO AXL Reception June 2nd 2018
AXL inhibition as a novel treatment of aggressive disease
Short presentations will be given by our investigators and AXL KOLs in a relaxed atmosphere.
Presentations will be made available in the investors section following the event.
For further details and to receive an invitation please contact: priya.nanduri@bergenbio.com
